Potential utility of Mycobacterium w vaccine in control of tuberculosis

Current Respiratory Medicine Reviews

Volumn 2, Issue 2, 2006, Pages 183-188

  Mathur, Murli L ^a  

^a Desert Medicine Research Centre India   (India)

Author keywords

Immunomodulator; Immunoprophylaxis; Immunotheraphy; Leprosy; Mycobacterium w; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; IMMUNOMODULATING AGENT; IMMUNOVAC; LEPROMIN; MACROPHAGE ACTIVATING FACTOR; MYCOBACTERIUM VACCINE; TUBERCULIN; TUBERCULOSTATIC AGENT;

CD4+ T LYMPHOCYTE; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG TREATMENT FAILURE; FATALITY; HEATING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INFECTION CONTROL; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE REACTION; INJECTION SITE ULCER; LEPROSY; LUNG TUBERCULOSIS; LYMPHOCYTE COUNT; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; REVIEW; SCAR FORMATION; SPUTUM;

EID: 33745915243     PISSN: 1573398X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339806776843120     Document Type: Review

References (68)

1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA 1999; 282: 677-686.
2. World Health Organization. WHO Report 2003: Global tuberculosis control. Geneva, Switzerland. World Health Organization. WHO/CDS/TB/2003 - 316. Available from: URL: http://www.who.int/gtb/Publications/globrep/ index.html.
3. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349:1269-1276.
4. Iseman MD. Tuberculosis. In Cecil Textbook of Medicine, Section Diseases due to Micobacteria, 21st Ed, Goldman ed., 2000: 1724-1732.
5. Schluger NW, Harkin TJ, Rom WN. Principles of therapy of tuberculosis in the modern era. In: Tuberculosis, Rom, Garay eds. Little Brown, New York, 1996: 751-759.
6. Ellner JJ. Multidrug-resistant tuberculosis. Adv Intern Med 1995; 40: 155-196.
7. Tuberculosis Research Centre, Annual Report 2003-2003. Relapse among Category I patients who have successfully completed treatment in the Model DOTS regimen. Chennai, India. pp. 21.
8. Schraufnagel DE. Tuberculosis treatment for the beginning of the next century. Int J Tuberculosis Lung Dis 1999; 3: 651-662.
9. Controlled clinical trial of levamisole in short-course chemotherapy for pulmonary tuberculosis. A Kenyan/Zambian/British Medical Research Council Collaborative Study. Am Rev Respir Dis 1989; 140: 990-995.
10. Stanford J, Stanford C, Grange J. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis. Front Biosci 2004; 9:1701-1719.
11. Mwinga A, Nunn A, Ngwira B, et al. Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial. Lancet 2002; 360:1050-1055.
12. De Bruyn G, Garner P. Mycobacterium vaccae immunotherapy for treating tuberculosis. Cochrane Database Syst Rev 2003; I:CDO01166.
13. Prem Raj P, Srivastava S, Jain SK, Srivastava BS, Srivastava R. Protection by live Mycobacterium habana vaccine against Mycobacterium tuberculosis H37Rv challenge in mice. Indian J Med Res 2003; 117:139-145.
14. Wakhlu A, Gaur SP, Kaushal GP, Misra A, Asthana P, Sircar AR. Response of Mycobacterium habana vaccine in patients with lepromatous leprosy and their household contacts. A pilot clinical study. Lepr Rev 2001; 72: 179-191.
15. Pedral-Sampaio DB, Netto EM, Brites C, et al. Use of Rhu-GM-CSF in pulmonary tuberculosis patients: results of a randomized clinical trial. Braz J Infect Dis 2003; 7: 245-252.
16. Johnson JL, Ssekasanvu E, Okwera A, et al. Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. Am J Respir Crit Care Med 2003; 168:185-191.
17. Yamada G, Shijubo N, Shigehara K, Okamura. H, Kurimoto M, Abe S. Increased levels of circulating interleukin-18 in patients with advanced tuberculosis. Am J Respir Crit Care Med 2000; 161: 1786-1789.
18. Tsao TCY, Huang CC, Chiou W-K, Yang P-Y, Hsieh M-J, Tsao K-C. Levels of interferon α and interleukin-2 receptor-β for bronchoalveolar lavage fluid and serum were correlated with clinical grade and treatment of pulmonary tuberculosis. Int J Tuberc Lung Dis 2002; 6: 720-727.
19. Yadava A, Mukherjee R. An immunodominant 30-kDa antigen of a candidate anti-leprosy vaccine, Mycobacterium w, shares T and B cell determinants with M. leprae and M. tuberculosis. Med Microbiol Immunol (Berl.) 1993; 182: 243-253.
20. Reddi PP, Amin AG, Khandekar PS, Talwar GP. Molecular definition of unique species status of Mycobacterium w; a candidate leprosy vaccine strain. Int J Lepr Other Mycobact Dis 1994; 62: 229-236.
21. Katoch VM. A report on the biochemical analysis of Mycobacterium w. Lepr India. 1981; 53: 385-389.
22. Prasad HK, Singh AK, Talwar GP. Ability of M. leprae, Mycobacterium w, and ICRC bacillus to produce macrophage activating factors from lymphocytes of leprosy patients. Lepr India 1978; 50: 539-549.
23. Fotedar A, Mehra NK, Mustafa AS, Talwar GP. Local reactions to intradermal instillation of Mycobacterium w and ICRC bacilli in mice. Lepr India 1978; 50: 520-533.
24. Ganju L, Mukherjee R, Batra HV, Talwar GP. Immuno-blot analysis of antigens of Mycobacterium w: a candidate anti-leprosy vaccine using monoclonal antibodies and patient sera. Zentralbl Bakteriol 1990; 273: 378-385.
25. Bhaskar S, Jain NK, Mukherjee R. Slide agglutination test for the diagnosis of pulmonary and extra-pulmonary tuberculosis. Tuber Lung Dis 1996; 77: 160-163.
26. Bhaskar S, Banavaliker JN, Hanif M. Large-scale validation of a latex agglutination test for diagnosis of tuberculosis. FEMS Immunol Med Microbiol 2003; 39: 235-239.
27. Singh IG, Mukherjee R, Talwar GP. Resistance to intravenous inoculation of Mycobacterium tuberculosis H37Rv in mice of different inbred strains following immunization with a leprosy vaccine based on Mycobacterium w Vaccine 1991; 9: 10-14.
28. Guleria I, Mukherjee R, Kaufmann SH. In vivo depletion of CD4 and CD8 T lymphocytes impairs Mycobacterium w vaccine-induced protection against M. tuberculosis in mice. Med Microbiol Immunol (Berl.) 1993; 182: 129-135.
29. Singh IG, Mukherjee R, Talwar GP, Kaufmann SH. In vitro characterization of T cells from Mycobacterium w-vaccinated mice. Infect Immun 1992; 60: 257-263
30. Chaudhuri S, Fotedar A, Talwar GP. Lepromin conversion in repeatedly lepromin negative BL/LL patients after immunization with autoclaved Mycobacterium w. Int J Lepr Other Mycobact Dis 1983; 51: 159-168
31. Kar HK, Sharma AK, Misra RS, et al. Induction of lepromin positivity by a candidate anti-leprosy vaccine Mycobacterium w in lepromin negative healthy contacts of multibacillary leprosy patients. Indian J Lepr 1992; 64: 495-500.
32. Katoch K. Immunotherapy of leprosy. Indian J Lepr 1996; 68: 349-361.
33. Talwar GP. An immunotherapeutic vaccine for multibacillary leprosy. Int Rev Immunol 1999; 18: 229-249.
34. Sharma P, Kar HK, Kaur H, et al. Induction of lepromin positivity and immunoprophylaxis in household contacts of multibacillary leprosy patients: a pilot study with a candidate vaccine, Mycobacterium w. Int J Lepr Other Mycobact Dis 2000; 68: 136-142.
35. Natarajan M, Katoch K, Bagga AK, Katoch VM. Histological changes with combined chemotherapy and immunotherapy in highly bacillated lepromatous leprosy. Acta Leprol 1992; 8: 79-86.
36. Walia R, Sarathchandra KG, Pandey RM, et al. Field trials on the use of Mycobacterium w vaccine in conjunction with multidrug therapy in leprosy patients for immunotherapeutic and immunoprophylactic purposes. Lepr Rev 1993; 64: 302-311.
37. Zaheer SA, Suresh NR, Kar HK, et al. Immunological upgrading with combined immunotherapy and chemotherapy in a lepromatous leprosy patient: a case report. Lepr Rev 1991; 62: 297-302.
38. Kar HK, Sharma AK, Misra RS, et al. Reversal reaction in multibacillary leprosy patients following MDT with and without immunotherapy with a candidate for an antileprosy vaccine, Mycobacterium w. Lepr Rev 1993; 64: 219-226.
39. Zaheer SA, Misra, RS, Sharma AK, et al. Immunotherapy with Mycobacterium w vaccine decreases the incidence and severity of type 2 (ENL) reactions. Lepr Rev 1993; 64: 7-14.
40. 21. Talwar GP, Zaheer SA, Mukherjee R, et al. Immunotherapeutic effects of a vaccine based on a saprophytic cultivable mycobacterium, Mycobacterium w in multibacillary leprosy patients. Vaccine 1990; 8: 121-129.
41. Talwar GP, Zaheer SA, Suresh NR, et al. Immunotherapeutic trials with a candidate anti-leprosy vaccine based on Mycobacterium w. Trop Med Parasitol 1990; 41: 369-370.
42. Zaheer SA, Beena. KR, Kar HK, et al. Addition of immunotherapy with Mycobacterium w vaccine to multi-drug therapy benefits multibacillary leprosy patients. Vaccine 1995; 13: 1102-1110.
43. Sharma P, Kar HK, Misra RS, et al. Induction of lepromin positivity following immuno-chemotherapy with Mycobacterium w vaccine and multidrug therapy and its impact on bacteriological clearance in multibacillary leprosy: report on a hospital-based clinical trial with the candidate antileprosy vaccine. Int J Lepr Other Mycobact Dis 1999; 67: 259-269.
44. De Sarkar A, Kaur I, Radotra BD, Kumar B. Impact of combined Mycobacterium w vaccine and 1 year of MDT on multibacillary leprosy patients. Int J Lepr Other Mycobact Dis 2001; 69: 187-194.
45. Kaur I, Dogra S, Kumar B, Radotra BD. Combined 12-month WHO/MDT MB regimen and Mycobacterium w vaccine in multibacillary leprosy: a follow-up of 136 patients. Int J Lepr Other Mycobact Dis 2002; 70: 174-181.
46. Sharma P, Kar HK, Misra RS, et al. Disabilities in multibacillary leprosy following multidrug therapy with and without immunotherapy with Mycobacterium w antileprosy vaccine. Int J Lepr Other Mycobact Dis 1999; 67: 250-258.
47. Sharma P, Misra RS, Kar HK, et al. Mycobacterium w vaccine, a useful adjuvant to multidrug therapy in multibacillary leprosy: a report on hospital based immunotherapeutic clinical trials with a follow-up of 1-7 years after treatment. Lepr Rev 2000; 71: 179-192.
48. Katoch K, Katoch VM, Natrajan M, et al. Treatment of bacilliferous BL/LL cases with combined chemotherapy and immunotherapy, Int J Lepr Other Mycobact Dis 1995; 63: 202-212.
49. Sharma P, Kar HK, Misra RS, et al. Reactional states and neuritis in multibacillary leprosy patients following MDT with/without inummotherapy with Mycobacterium w antileprosy vaccine. Lepr Rev 2000; 71: 193-205.
50. Gupte MD, Vallishayee RS, Anantharaman DS, Britto RL, Nagaraju B. Sensitization and reactogenicity of two doses of candidate antileprosy vaccine Mycobacterium w. Indian J Lepr 1996; 68: 315-324.
51. Gupte MD, Vallishayee RS, Anantharaman DS, et al. Comparative leprosy vaccine trial in South India. Ind J Lepr 1998; 70: 369-388
52. Katoch K, Natrajan MB, Chauhan DS, Katoch VM and Sachan AS. Determining the point prevalence of tuberculosis in M w vaccinated population of Ghatampur, Kanpur area (DBT funded Project). Annual Report Central JALMA Institute for Leprosy 2002; 67-68.
53. Sharma P, Mukherjee R, Talwar GP, et al. Immunoprophylactic effects of the anti-leprosy Mw vaccine in household contacts of leprosy patients: clinical field trials with a follow up of 8-10 years. Lepr Rev 2005; 76:127-43.
54. Patel N, Deshpande MM, Shah M. Effect of an immumodulator containing Mycobacterium w on sputum conversion in pulmonary tuberculosis. J Indian Med Assoc 2002; 100: 191-193.
55. Patel N, Trapathi SB. Improved cure rates in pulmonary tuberculosis category II (retreatment) with Mycobacterium w. J Indian Med Assoc 2003; 101: 680-682.
56. Choudhary CR, Joshi V and Luhadia SK. Mycobacterium w as an adjunct to chemotherapy in Cat II Pulmonary tuberculosis. Paper presented at National Conference on Pulmonary Diseases, Jaipur, INDIA, 20-24 November 2002.
57. Choudhary CR and Luhadia SK. Mycobacterium w as an adjunct to chemotherapy in Cat II Pulmonary tuberculosis. Paper presented at Second State Conference on Tuiberculosis and Respiratory Disease, Dr. S. N. Medical College, Jodhpur, INDIA. January 18-19, 2003.
58. Sharma RS and Luhadia SK. Mycobacterium w as an adjunct to chemotherapy in Cat I Pulmonary tuberculosis. Paper presented at Second State Conference on Tuiberculosis and Respiratory Disease, Dr. S. N. Medical College, Jodhpur, INDIA. January 18-19, 2003.
59. Kharkar R. Immune recovery in HIV with Mycobacterium w. J Indian Med Assoc 2002; 100: 578-9.
60. Laxman Y. Tuberculin conversion in HIV seropositives. J Indian Med Assoc 2002; 100: 622-3.
61. Silveira H, Ordway D, Dockrell H, Jackson M, Ventura F - Cell-mediated immune responses to mycobacterial antigens in patients with pulmonary tuberculosis and HIV infection. Clin Exp Immunol 1997; 110: 26-34.
62. Rath N, Kar HK. Efficacy of intradermal heat-killed Mycobacterium w in psoriasis: a pilot study. Int J Dermatol 2003; 42: 756-757.
63. Kumar B, Sandhu K, Kaur I. Role of Mycobacterium w vaccine in the management of psoriasis. Br J Dermatol 2005; 152: 380-382.64.
64. Sur PK, Dastidar AG. Role of Mycobacterium w as adjuvant treatment of lung cancer (non-small cell lung cancer). J Indian Med Assoc 2003; 101: 118-120.
65. Chaudhuri P, Mukhopadhyay S. Bladder preserving approach for muscle invasive bladder cancer-role of mycobacterium w. J Indian Med Assoc 2003; 101: 559-560.
66. Sarkar SK and Dasgupta C. Role of mycobacterium W as an adjuvant treatment of head & neck cancer - A randomised trial. J Clin Oncol 2005; 23(Suppl):5588S.
67. Dave RI, Shah SV, Patel KM, Tripathi UB, Kapadia AS and Panchal HP. Use of immunomodulater mycobacterium w vaccine for palliative treatment in advanced & incurable cancer patients. J Clin Oncol 2005; 23 (Suppl):2592S.
68. Pant MC, Hadi R, Prasad R, et al. Role of immuno-therapy as a adjuvant treatment in advance head & neck cancer, patient receiving chemo radiotherapy. J Clin Oncol 2005; 23(Suppl): 2598S.